🔥🐔 BizChicken 🐔🔥

Companies Similar to FibroGen, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Galafold

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for rare diseases, with products including Galafold for Fabry disease and developing therapies for Pompe and CLN3 diseases.

Tags: Biotechnology, Fabry Disease, Galafold, Gene Therapy, Pharmaceuticals, Pompe Disease, Rare Diseases

Symbol: FOLD

Recent Price: $9.41

Industry: Biotechnology

CEO: Mr. Bradley L. Campbell M.B.A.

Sector: Healthcare

Employees: 500

Address: 3675 Market Street, Philadelphia, PA 19104

Phone: 215 921 7600

Leadership

  • Bradley L. Campbell, President and Chief Executive Officer
  • Simon Harford, Chief Financial Officer
  • David Clark, Chief People Officer
  • Jayne C. Gershkowitz, Chief Patient Advocate
  • Sébastien Martel, Chief Business Officer
  • Ellen S. Rosenberg, Chief Legal Officer
  • Jeffrey P. Castelli, Chief Development Officer
  • Stephen Arnold, Chief, Head of Global Rare Disease
  • Julie Yu, Chief Program Officer
  • Pat O’Sullivan, Chief Technical Operations Officer
  • Jill Weimer, Chief Science Officer
  • Patrik Florencio, Global Chief Compliance and Risk Officer

Last updated: 2024-12-31

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

losmapimod and FTX-6058

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.

Tags: FTX-6058, biopharmaceutical, clinical-stage, facioscapulohumeral muscular dystrophy, genetically defined diseases, hemoglobinopathies, losmapimod, sickle cell disease

Symbol: FULC

Recent Price: $4.68

Industry: Biotechnology

CEO: Mr. Alexander C. Sapir

Sector: Healthcare

Employees: 76

Address: 26 Landsdowne Street, Cambridge, MA 02139

Phone: 617 651 8851

Last updated: 2024-12-31

FibroBiologics, Inc. Common Stock

FibroBiologics, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

Cybro Cell

Fibro Biologics, Inc. is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for various diseases, including degenerative disc disease, multiple sclerosis, and wound healing, among others.

Tags: biotechnology, cancer treatment, cell therapy, degenerative disc disease, fibroblasts, multiple sclerosis, psoriasis, wound healing

Symbol: FBLG

Recent Price: $2.24

Industry: Biotechnology

CEO: Mr. Peter O'Heeron

Sector: Healthcare

Employees: 10

Address: 455 East Medical Center Boulevard, Houston, null 77598

Phone: 281 651 5150

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

RP5063

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for unmet medical needs, particularly in central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.

Tags: CNS diseases, RP1208, RP5063, biopharmaceutical, clinical-stage, therapeutics

Symbol: RVPH

Recent Price: $1.81

Industry: Biotechnology

CEO: Dr. Laxminarayan Bhat Ph.D.

Sector: Healthcare

Employees: 15

Address: 19925 Stevens Creek Boulevard, Cupertino, CA 95014

Phone: 408 501 8881

Last updated: 2024-12-31

180 Life Sciences Corp.

180 Life Sciences Corp. logo
Market Cap: Lowest
Employees: Lowest

Therapeutics for chronic pain, inflammation, fibrosis, and inflammatory diseases

1180 Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis, using platforms such as fibrosis and anti-TNF, synthetic CBD analogs, and a7n ACh R.

Tags: CBD analogs, a7n ACh R, anti-TNF, biotechnology, chronic pain, clinical-stage, fibrosis, inflammation, therapeutics

Symbol: ATNF

Recent Price: $2.98

Industry: Biotechnology

CEO: Mr. Lloyd Blair Jordan L.L.B., M.B.A.

Sector: Healthcare

Employees: 4

Address: Building 4, Palo Alto, CA 94306

Phone: 650 507 0669

Last updated: 2024-11-08

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

FibroGen, Inc.

FibroGen, Inc. logo
Market Cap: Lowest
Employees: Medium

Roxadustat, Pamrevlumab

Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.

Tags: anemia, antibody, biopharmaceutical, cancer, kidney disease, pulmonary fibrosis, therapeutics

Symbol: FGEN

Recent Price: $0.53

Industry: Biotechnology

CEO: Mr. Thane Wettig

Sector: Healthcare

Employees: 486

Address: 409 Illinois Street, San Francisco, CA 94158

Phone: 415 978 1200

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

PLN-74809

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.

Tags: biopharmaceutical, clinical trials, fibrosis, integrin inhibitor, therapies

Symbol: PLRX

Recent Price: $12.79

Industry: Biotechnology

CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.

Sector: Healthcare

Employees: 166

Address: 260 Littlefield Avenue, South San Francisco, CA 94080

Phone: 650 481 6770

Last updated: 2024-12-31

Pulmatrix, Inc.

Pulmatrix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Pulmazole, PUR1800, PUR3100

Pulmatrix, Inc., a clinical stage biotechnology company, develops inhaled therapies for respiratory and other diseases with unmet medical needs, using its i SPERSE technology for drug delivery.

Tags: biotechnology, i SPERSE technology, inhaled therapies, respiratory diseases

Symbol: PULM

Recent Price: $6.86

Industry: Biotechnology

CEO: Mr. Peter Ludlum CMA, MBA

Sector: Healthcare

Employees: 22

Address: 99 Hayden Avenue, Lexington, MA 02421

Phone: 781 357 2333

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

RenovoRx, Inc.

RenovoRx, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renovo Gem

Renovo Rx, Inc. is a clinical-stage biopharmaceutical company focusing on developing therapies for the treatment of solid tumors, with its lead product candidate, Renovo Gem, in Phase III clinical trials for locally advanced pancreatic cancer.

Tags: Renovo Gem, biopharmaceutical, clinical trials, pancreatic cancer, solid tumors

Symbol: RNXT

Recent Price: $1.39

Industry: Biotechnology

CEO: Mr. Shaun R. Bagai

Sector: Healthcare

Employees: 8

Address: 4546 El Camino Real, Los Altos, CA 94022

Phone: 650 284 4433

Leadership

  • Shaun R. Bagai, Director and Chief Executive Officer
  • Ramtin Agah, MD, Chairman, Chief Medical Officer, and Founder
  • Leesa Gentry, Chief Clinical Officer
  • Ronald B. Kocak, CPA, VP Controller and Principal Accounting Officer
  • Ryan Witt, Senior Vice President, Head of Corporate Strategy and Partnerships
  • Imtiaz Qureshi, MD, Director of Imaging
  • Angela Macfarlane, CEO of Perceive Biotherapeutics, Inc.
  • Laurence J. Marton, MD, Director
  • Una S. Ryan, PhD, OBE, Director
  • Robert J. Spiegel, Director

Last updated: 2024-12-31

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Low

Tamibarotene

Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.

Tags: acute myeloid leukemia, biopharmaceutical, cancer treatment, gene control, myelodysplastic syndrome, pharmaceutical development

Symbol: SYRS

Recent Price: $0.25

Industry: Biotechnology

CEO: Mr. Conley Chee

Sector: Healthcare

Employees: 68

Address: 35 CambridgePark Drive, Cambridge, MA 02140

Phone: 617 744 1340

Leadership

  • Conley Chee, President and Chief Executive Officer
  • Jason Haas, Chief Financial Officer
  • Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
  • Lisa Roberts, VP Human Resources
  • David A. Roth, M.D., Chief Medical Officer
  • Kristin Stephens, Chief Development Officer

Last updated: 2024-12-31

VYNE Therapeutics Inc.

VYNE Therapeutics Inc. logo
Market Cap: Lowest
Employees: Lowest

FCD105, FMX114, VYN201, VYN202

VYNE Therapeutics Inc. is a pharmaceutical company specializing in developing therapeutics for immuno-inflammatory conditions. Key products include FCD105 for acne vulgaris, FMX114 for atopic dermatitis, and BET inhibitors VYN201 and VYN202 for skin and other immuno-inflammatory diseases.

Tags: BET inhibitors, acne vulgaris, atopic dermatitis, immuno-inflammatory, pharmaceutical, therapeutics

Symbol: VYNE

Recent Price: $3.19

Industry: Biotechnology

CEO: Mr. David T. Domzalski

Sector: Healthcare

Employees: 10

Address: 520 U.S. Highway 22, Bridgewater, NJ 08807

Phone: 800 775 7936

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31